Search
Sutai Pharmaceutical Announces Phase I Clinical Study Summary for STSP-0902 Eye Drops
2025-08-22 /
Read about 0 minute
Author：小编
Sutai Pharmaceutical Company has proudly announced the successful completion of Phase I clinical studies for its STSP-0902 eye drops, currently under research and development. The results demonstrate the medication's excellent safety profile and tolerability, with the majority of adverse events reported as mild. Notably, pharmacokinetic tests revealed that the drug remained detectable in tears up to six hours after a single administration. These promising findings offer robust support for the progression of STSP-0902 into subsequent clinical trials, specifically targeting patients with neurotrophic keratitis.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
